Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi NextCODE to Sequence 400,000 Irish Genomes in $400 Million Study; Closes $200 Million C Round

publication date: Nov 27, 2018

WuXi NextCODE announced plans for a $400 million genomics database based on sequencing the genomes of 400,000 Irish citizens -- 10% of the population. As part of the effort, WuXi will acquire Genomics Medicine Ireland (GMI) of Dublin, which will become its European headquarters. NextCODE also closed a $200 million Series C financing led by Ireland Strategic Investment Fund (ISIF), which contributed $70 million of the round. Previously, ISIF was the lead shareholder in GMI. The project will eventually add 600 jobs to GMI/NextCODE's Dublin facilities. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital